4SC AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.9 EUR | -1.25% |
|
-10.23% | -10.73% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 436K 470K | Sales 2023 | 304K 327K | Capitalization | 89.51M 96.43M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -15.08M | Net income 2023 | -8M -8.62M | EV / Sales 2022 | -4.31 x |
| Net cash position 2022 | 14.82M 15.97M | Net cash position 2023 | 5.22M 5.62M | EV / Sales 2023 | 277 x |
| P/E ratio 2022 |
-0.9
x | P/E ratio 2023 |
-10.9
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.68% |
More Fundamentals
* Assessed data
| 1 day | -1.25% | ||
| 1 week | -10.23% | ||
| 1 month | -3.89% | ||
| 3 months | -15.05% | ||
| 6 months | +3.27% | ||
| Current year | -10.73% |
1 week
7.90
8.60
1 month
7.909.70
Current year
7.0011.20
1 year
2.9618.10
3 years
1.1018.10
5 years
1.1018.10
10 years
1.1043.25
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 7.9 | -1.25% | 1,590 |
| 24-05-09 | 8 | -4.76% | 1,500 |
| 24-05-08 | 8.4 | -2.33% | 2,065 |
| 24-05-07 | 8.6 | +4.37% | 200 |
| 24-05-06 | 8.24 | -6.36% | 1,297 |
Delayed Quote Deutsche Boerse AG, May 10, 2024 at 10:52 am EDT
More quotes
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Companyâs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Calendar
2024-06-19
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.73% | 86.05M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- VSC Stock